Novartis supportive of Donald Trump's drug policy: CEO Vasant Narasimhan
Novartis is supportive of Donald Trump's continued campaign to lower drug prices, won't raise prices of its drugs for the remainder of this year, says CEO Vasant Narasimhan in an interview
Announcement under Regulation 30 (LODR)-Newspaper Publication
Dear Sirs, Please find enclosed herewith the copies of the notice under Section 201 of the Companies Act, 2013 published in the Newspapers viz. 'Financial Express' and 'Navshakti' today. This is for your information and record.
Donald Trump says drug prices will drop really, really substantially'
Donald Trump says the prices of prescription drugs made by Pfizer, Novartis and other pharmaceutical companies are too high Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Novartis India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Shareholder Meeting / Postal Ballot-Outcome of AGM
The shareholders approved the following: Audited Statement of Profit and Loss Account for the year ended March 31, 2018 and the Balance Sheet as on that date together with the Reports of the Directors and the Auditors thereon; Dividend of Rs 10/- per equity share of Rs. 5 each; Re-appointment of Ms. Monaz Noble (DIN: 03086192) as a Director who retired by rotation;... Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results of the 70th Annual General Meeting Dear Sirs, Please find enclosed the information in terms of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer's Report as per Section 109 of the Companies Act, 2013, in relation to the Annual General Meeting of Novartis India Limited held on July 27, 2018.... Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Dear Sirs, We refer to our letter dated June 27, 2018, informing you about the Board Meeting of Novartis India Limited that was scheduled for today. Please note that the Board of Directors of the Company met today at 11.00 a.m. and the meeting concluded at 02.30 p.m. The following items were considered and approved: 1. Financial results for the quarter ended June 30, 2018 along with the Limited Review Report provided by M/s, Deloitte... Results For The Quarter Ended June 30, 2018
We refer to our letter dated June 27, 2018, informing you about the Board Meeting of Novartis India Limited that was scheduled for today. Please note that the Board of Directors of the Company met today at 11.00 a.m. and the meeting concluded at 02.30 p.m. The following items were considered and approved: 1. Financial results for the quarter ended June 30, 2018 along with the Limited Review Report provided by M/s, Deloitte Haskins & Sells LLP, Statutory Auditors of the Company....
Novartis to pay as much as $1 billion for skin drug rights
Novartis will pay 95 million upfront and later payments of up to 850 million based on the drug reaching certain regulatory, commercial and sales goals Shareholding for the Period Ended June 30, 2018
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here